 |
|
|
| |
High interest in long-acting injectable
HIV pre-exposure prophylaxis among nationwide
online sample of United States men who have sex with men, 2019
|
| |
| |
IAS 2021 July 18-22
Travis Sanchez1, Mona Rai1, S. Wilson Beckham2, M. Keith Rawlings3, Alex Rinehart3, Supriya Sarkar3, Patrick Sullivan1, Maria Zlotorzynska1, Vani Vannappagari3
1 Rollins School of Public Health, Emory University; 2 Johns Hopkins Bloomberg School of Public Health; 3 ViiV Healthcare
Conflict Statement : Study was conducted with financial and technical support from ViiV Healthcare, a pharmaceutical company that is developing a long-acting injectable HIV pre-exposure prophylaxis medication
|
| |
|
|
|
|
|
